Navigation Links
First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System
Date:3/17/2008

WILMINGTON, Mass., March 17 /PRNewswire/ -- OmniSonics Medical Technologies, Inc., a developer of advanced medical devices for use in the treatment of vascular disease, announced today that it has enrolled its first patient in the SONIC I Clinical Registry. SONIC I is a prospective, multi-centered U.S. registry study of the company's OmniWave(TM) Endovascular System (OES) in patients undergoing percutaneous mechanical thrombectomy of acute deep vein thrombosis (DVT). All patients enrolled in the SONIC I are scheduled for follow-up at 30 days and 6 months following the OmniWave procedure. The first patient was enrolled by Daniel Clair, M.D., Chairman of Vascular Surgery at The Cleveland Clinic.

"The Cleveland Clinic is excited to participate in the SONIC I clinical trial with the OmniWave Endovascular System," said Dr. Clair. "The OmniWave System has the potential to offer physicians an effective alternative to current pharmacological and mechanical treatments for deep vein thrombosis (DVT)."

In response to this important milestone, Richard Ganz, President and CEO of OmniSonics Medical Technologies, said, "We continue to be encouraged by the positive outcomes the first physicians are having with the OmniWave Endovascular System. Enrolling our first patient in the SONIC I Clinical Registry is a key step in our contribution to providing tools to physicians for the treatment of DVT."

In September 2007, OmniSonics received clearance from the Food and Drug Administration (FDA) to market its catheter-based OmniWave Endovascular System for the infusion of physician specified fluids, including thrombolytics, and for the removal of thrombus in the peripheral vasculature.

OmniSonics Medical Technologies, Inc. is scheduled to exhibit the OmniWave Endovascular System at the Society for Interventional Radiology (SIR) Meeting to be held March 15-20 in Washington, DC.

The OmniWave Endovascular System is based on patented OmniWave technology, the first minimally invasive catheter-based technology that delivers low-power, transverse ultrasonic energy to remove thrombus quickly, safely, and effectively. Thrombus (also known as a blood clot) occurs in a number of conditions including deep vein thrombosis (DVT) and acute limb ischemia. DVT affects approximately 2 million people in the U.S. every year, and acute limb ischemia affects over 250,000 people in the U.S. every year.

About OmniSonics Medical Technologies, Inc.

OmniSonics Medical Technologies, Inc., based in Wilmington, MA, is a venture-backed medical device company focused on developing breakthrough products for the treatment of vascular disease. The Company's products are based on its patented OmniWave technology, the first technology capable of delivering low-power ultrasonic energy around the active length of a small diameter wire in a diseased blood vessel. OmniWave technology is designed to have broad applications in vascular disease.

Contact: Len Farris

Vice President, Marketing

(978) 657-9980 x501

lfarris@omnisonics.com


'/>"/>
SOURCE OmniSonics Medical Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Innocoll Announces Dosing of First Patient in a Second US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
3. Mobidiag Releases First Microarray Based Rapid Test for Herpesvirus Identification
4. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
5. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
6. First-Ever Cancer and Careers Seminar Debuts in Orange County
7. Pharmaxis First Steps into China
8. NIOXIN(R) Delivers the Future to Scalp and Hair Care, Introduces the First Genetic Test to Determine the Likelihood of Hair Loss
9. Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve
10. First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference
11. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... New York , December 9, 2016 ... states that the top five players in the  Global ... 62.7% in the overall market in 2015. Players such ... Perkin Elmer have remained dominant in the global market ... efforts to ensure product innovation. Product upgrades and timely ...
(Date:12/8/2016)... 8, 2016  The Board of Directors of the ... Western Pennsylvania,s only pure life sciences investment ... with the succession plan developed by the Nominating and ... James (Jim) F. Jordan is selected to ... John W. Manzetti , who is elected to the ...
(Date:12/8/2016)... , December 8, 2016 AskLinkerReports.com ... comprehensive analysis, titled Global Amyloglucosidase Industry 2016 Market Research Report. ... application, and industry chain overview are all covered in the ... analysis, and investment return analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... the FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, ... require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016   Neurotechnology , ... object recognition technologies, today released FingerCell 3.0, ... recognition solutions that run on low-power, low-memory ... using less than 128KB of memory, enabling ... that have limited on-board resources, such as: ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/21/2016)... 21, 2016   Neurotechnology , a provider ... today announced that the MegaMatcher On Card fingerprint ... for the NIST Minutiae Interoperability Exchange (MINEX) ... mandatory steps of the evaluation protocol. ... test of fingerprint templates used to establish compliance ...
Breaking Biology News(10 mins):